Patents Examined by Michelle S Horning
  • Rabies glycoprotein virus-like particles (VLPS)
    Patent number: 10086065
    Abstract: The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 2, 2018
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Ye Liu
  • Influenza vaccine and therapy
    Patent number: 10080792
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 25, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • Universal virus-like particle (VLP) influenza vaccines
    Patent number: 10080796
    Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: September 25, 2018
    Assignee: TECHNOVAX, INC.
    Inventors: Jose M. Galarza, George R. Martin
  • Composition for treating HBV infection
    Patent number: 10076570
    Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: September 18, 2018
    Assignee: Transgene S.A.
    Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
  • Therapeutic use of specific ligand in MSRV associated diseases
    Patent number: 10059758
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: August 28, 2018
    Assignee: GENEURO SA
    Inventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 10052375
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 21, 2018
    Assignee: Zoetics Services LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Compositions and methods for detecting HEV nucleic acid
    Patent number: 10053742
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: August 21, 2018
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Kui Gao, Edgar O. Ong, Jennifer Cole, Jeffrey M. Linnen
  • Chemically activated nanocapsid functionalized for cancer targeting
    Patent number: 10053494
    Abstract: Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: August 21, 2018
    Assignee: The Regents of the University of California
    Inventors: R. Holland Cheng, Li Xing, Chun Chieh Chen, Marie Stark
  • Compositions and methods for detecting HEV nucleic acid
    Patent number: 10047406
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: August 14, 2018
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Kui Gao, Edgar O. Ong, Jennifer Cole, Jeffrey M. Linnen
  • Codon optimized recombinant phage and methods of using same
    Patent number: 10039795
    Abstract: Composition and methods for the detection of one or more target microbe(s) are provided. Compositions of the disclosure include at least one recombinant phage capable of infecting a target microbe, said phage comprising at least a capsid protein sequence, a ribosome binding site, and a codon-optimized marker. Compositions of the disclosure may further include an aqueous solution that enhances the ability to detect marker expression upon phage infection of the target microbe. In some embodiments the target microbe include is Listeria.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 7, 2018
    Assignee: Institute for Environmental Health, Inc.
    Inventors: Michael Sandor Koeris, Jayson L. Bowers, Daniel Robert Brownell, Edyta Krzymanska-Olejnik, Robert Patrick Shivers, Michael Cappillino
  • Multiprotein assemblies
    Patent number: 10036755
    Abstract: The present invention provides compositions and methods of use in investigations of the formation of mulitprotein assemblies implicated in disease. Also provided are assays for screening candidate compounds of potential utility in preventing and/or treating such diseases by preventing the assembly of or disrupting the function of multiprotein assemblies.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: July 31, 2018
    Assignee: Prosetta Antiviral, Inc.
    Inventors: Vishwanath R. Lingappa, Debendranath Dey
  • Use of EGFR pathway inhibitors to increase immune responses to antigens
    Patent number: 10034931
    Abstract: This disclosure relates to using EGFR pathway inhibitors in combination with compositions comprising an antigen to increase, elicit, or improve an antigen or vaccine-induced immune response. In certain embodiments, the EGFR pathway inhibitor is administered under conditions such that memory cells to the antigen are formed in a subject. In certain embodiments, the composition is a vaccine. In certain embodiments, the EGFR pathway inhibitor and vaccine are administered to the skin epidermis or dermis.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: July 31, 2018
    Assignee: Emory University
    Inventors: Brian P. Pollack, Richard W. Compans, Joanna A. Pulit-Penaloza, Ioanna Skountzou
  • Clostridium perfringens bacteriophage Clo-PEP-1 and use thereof for inhibiting proliferation of clostridium perfringens
    Patent number: 10028984
    Abstract: The present invention relates to a Myoviridae bacteriophage Clo-PEP-1 that is isolated from the nature and can kill Clostridium perfringens cells specifically, which has the genome represented by nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12664BP), and a method for preventing and treating the infections of Clostridium perfringens cells using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 24, 2018
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Suk Hwang Park
  • Coliphage biosensor
    Patent number: 10012594
    Abstract: Disclosed are methods, apparatuses, and genetically modified bacteria that may be used to detect bacteriophages in a sample. In some embodiments, a rapid detection test is disclosed to test for the presence of coliphages which may indicate the presence of human or animal waste contamination in water samples.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: July 3, 2018
    Inventors: James K. Campbell, Lyuda Trokhina
  • Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
    Patent number: 10010499
    Abstract: The present invention relates to microneedle vaccine formulations, as well as methods of use thereof to provide animals, including canines, protective immunity against infection and disease caused by rabies viruses. Once placed onto the skin of the animals, the microneedle formulations dissolve quickly into the surrounding skin, where the antigens then elicit in the animals high and protective levels of rabies virus neutralizing antibodies.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: July 3, 2018
    Assignees: MERIAL INC., Georgia Tech Research Corporation
    Inventors: Yu-Wei Chiang, Mark R. Prausnitz, Kristopher Daniel DeWitt, Jaya Arya
  • Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
    Patent number: 10006050
    Abstract: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: June 26, 2018
    Assignee: MERIAL, INC.
    Inventors: Teshome Mebatsion, Jules Maarten Minke, Frederic David
  • Methods for detection of anti-cytomegalovirus neutralizing antibodies
    Patent number: 10006096
    Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: June 26, 2018
    Assignee: Variation Biotechnologies Inc.
    Inventors: David E. Anderson, Jasminka Bozic, Barthelemy Ontsouka
  • Influenza vaccine and therapy
    Patent number: 9999662
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 21, 2014
    Date of Patent: June 19, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark R. Alfenito, Mark Baer, Doris Bucher
  • Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
    Patent number: 9993545
    Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 12, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Methods of expanding bacteriophage host-range and bacteriophage produced by the methods
    Patent number: 9988608
    Abstract: A method of producing novel bacteriophages with expanded host-range and bacteriophages with expanded host ranges are disclosed. The method produces mutant phage strains which are infectious to a second host and can be more infectious to their natural host than in their natural state. The method includes repeatedly passaging a selected phage strain into bacterial cultures that contain varied ratios of its natural host bacterial strain with a bacterial strain that the phage of interest is unable to infect; the target-host. After each passage the resulting phage are purified and screened for activity against the target-host via double-overlay assays. When mutant phages that are shown to infect the target-host are discovered, they are further propagated in culture that contains only the target-host to produce a stock of the resulting mutant phage.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: June 5, 2018
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Kevin K. Crown, Joshua Santarpia